Get the Stockscreener App
19.66
2.16%
0.415
Acadia Pharmaceuticals Inc stock is traded at $19.66, with a volume of 561.33K.
It is up +2.16% in the last 24 hours and down -26.51% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
See More
Previous Close:
$19.25
Open:
$19.48
24h Volume:
561.33K
Relative Volume:
0.28
Market Cap:
$3.39B
Revenue:
$1.10B
Net Income/Loss:
$375.65M
P/E Ratio:
8.9537
EPS:
2.1963
Net Cash Flow:
$113.59M
1W Performance:
+0.43%
1M Performance:
-26.51%
6M Performance:
-9.63%
1Y Performance:
-9.54%
1-Day Range:
$19.28
$19.88
1-Week Range:
$18.39
$20.05
52-Week Range:
$18.39
$30.96
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
19.66 | 3.39B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-26 | Downgrade | UBS | Buy → Neutral |
| Mar-25-26 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-23-26 | Upgrade | Mizuho | Neutral → Outperform |
| Oct-21-25 | Initiated | Citigroup | Buy |
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
RBC keeps Outperform on ACADIA Pharmaceuticals stock at USD 37 - AD HOC NEWS
RBC reiterates Outperform on ACADIA Pharmaceuticals stock - AD HOC NEWS
Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value? - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Resolves Nuplazid Patent Dispute, Boosting Market Outlook - GuruFocus
RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments - Investing.com
Acadia Pharmaceuticals (ACAD) and Zydus Move to Dismiss Patent L - GuruFocus
ACADIA Pharmaceuticals Inc. (0A4W.IL) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc. (ACAD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance Australia
Acadia Pharmaceuticals stock hits 52-week low at $19.66 - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Yahoo Finance
Acadia debuts 63,000 sq. ft. Princeton office, biopharma hub designed by Ware Malcomb - Real Estate NJ
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - biospace.com
Acadia Pharmaceuticals (ACAD) Secures USPTO Notice of Allowance for Rett Syndrome Patent - GuruFocus
Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent - Yahoo Finance
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - simplywall.st
Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results - GuruFocus
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha
Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says - Yahoo Finance
Ware Malcomb says construction finished on Acadia Pharmaceuticals’ Princeton office - ROI-NJ
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - Yahoo Finance
Biotech Rattled On Surprise Setback For Alzheimer's Drug - Investor's Business Daily
ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25 - AlphaStreet
Why Is Acadia Pharmaceuticals Stock Tumbling Today?ACADIA Pharmaceuticals (NASDAQ:ACAD) - benzinga.com
Acadia Pharmaceuticals: Remlifanserin Is In Trouble (NASDAQ:ACAD) - Seeking Alpha
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data - Yahoo Finance
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward - biospace.com
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint - Yahoo Finance
ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint - Yahoo Finance
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease PsychosisSlideshow (NASDAQ:ACAD) 2026-09-24 - Seeking Alpha
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Pharma (ACAD): Will Remlifanserin Data Unlock A New Growth Opportunity? - RTTNews
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Form 8K ACADIA Pharmaceuticals Inc For: 11 September By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals announces preliminary court approval of settlement in stockholder derivative action - Investing.com
Acadia Pharmaceuticals announces preliminary court approval of settlement in stockholder derivative action - Investing.com Australia
Acadia Pharmaceuticals announces preliminary court approval of settlement in stockholder derivative action - Investing.com Canada
Form 8K ACADIA Pharmaceuticals Inc For: 11 September By Investing.com - Investing.com Canada
Acadia Pharmaceuticals Announces Preliminary Court Approval of Stockholder Derivative Lawsuit Settlement - Kalkine Media
ACADIA PHARMACEUTICALS INC Reports Material Event - Stock Titan
Acadia Pharmaceuticals announces preliminary court approval of settlement in stockholder derivative action - Investing.com Nigeria
Avoiding Lag: Real-Time Signals in (ACAD) Movement - Stock Traders Daily
Acadia Pharma GLP-1 Receptor Agonists Weight Management Diabetes Treatments *zLHGd49l0* - akhmetovfoundation.org
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acadia Pharmaceuticals Inc Stock (ACAD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 06 '26 |
Sale |
29.22 |
14,292 |
417,604 |
67,828 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 05 '26 |
Option Exercise |
17.84 |
5,849 |
104,346 |
73,677 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 05 '26 |
Sale |
29.00 |
5,849 |
169,638 |
67,828 |
| Schneyer Mark C. | Officer |
Aug 05 '26 |
Proposed Sale |
27.15 |
5,849 |
158,800 |
0 |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev |
Jul 30 '26 |
Sale |
26.13 |
16,558 |
432,663 |
18,994 |
| Kihara James | Officer |
Jun 26 '26 |
Proposed Sale |
26.00 |
11,421 |
297,000 |
0 |
| JAMES K KIHARA | Officer |
May 26 '26 |
Proposed Sale |
21.18 |
5,401 |
114,394 |
0 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
May 26 '26 |
Sale |
21.18 |
5,401 |
114,393 |
24,509 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
May 04 '26 |
Sale |
21.79 |
1,332 |
29,024 |
29,129 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
May 04 '26 |
Sale |
21.79 |
3,506 |
76,396 |
66,145 |
5.42%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):